# Case Report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition

## TL;DR

A patient with advanced melanoma achieved a complete response using a combination of a new radiation technique and immunotherapy drugs.

## Contribution

This case report demonstrates a complete pathologic response in bulky melanoma using SFRT and dual checkpoint inhibition.

## Key findings

- A 12 cm lung melanoma mass showed complete pathologic response after SFRT and dual nivolumab/ipilimumab.
- The patient remained disease-free for 2.5 years, including over a year without systemic therapy.
- The results suggest a potential synergy between SFRT and immunotherapy in treating advanced melanoma.

## Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced melanoma, though response rates remain limited in bulky disease. Herein, we report the case of a complete pathologic response following combination spatially fractionated radiation therapy (SFRT) and dual nivolumab and ipilimumab for a 12 cm right lung melanoma mass, with subsequent lobectomy revealing no viable tumor cells. Now disease free 2.5 years after treatment, including more than 1 year off all systemic therapy, this case highlights the potential synergy between SFRT and immunotherapy in advanced melanoma management.